You are here

Biogen Makes Play for Big Stake in Samsung Bioepis

Puts down $700 million to buy nearly 50% of Samsung.

In a move analysts of the biosimilars market have been looking for, Biogen decided to jump into a pool with both feet that it merely stuck its toe in in 2011. Biogen slapped down $700 million in its bid to buy 49.9% of Samsung Bioepis, Endpoints News reports.

Apparently, the move springs from a change in CEOs. Back in 2011, it was George Scangos. Today it is Michel Vounatsos. “This option allows us to increase our ownership share in a leading biosimilar company at what we believe are attractive terms,” Vounatsos tells Endpoints News. “We look forward to building an important relationship with Samsung BioLogics.”

Source: Endpoints News

Recent Headlines

Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs
Mesh Implants, Now Banned by FDA, Work as Well as Hysterectomy
One in Five Kids’ Office Visits Results in an Off-Label Rx
Disrupting Gut Microbiome Could Be Key
Drug Boosts Levels of Natural Endocannabinoids
Judicious Use of Antibiotics May Not Be Enough To Defeat Bacteria That Carry On By Going Into a Dormant State
KRAS Oncogene Is a Problematic Target So Researchers Are Trying Workdarounds